Aspen Pharmacare considered destroying cancer medicines in order to raise prices in Europe by up to 4,000 euros , according to allegations made by the Times . The proposal was made in 2014 when the company was in dispute with the Spanish health service . Aspen , which has its European base in Dublin , raised the prices of some of its cancer drugs after purchasing the rights to the Cosmos drug portfolio from GlaxoSmithKline in 2009 . Although the cancer drugs were out of patent , they had no competition . apple was also able to introduce a loophole that enables companies to raise prices once brand names are dropped .
Aspen Pharmacare considered destroying cancer medicines in order to raise prices in Europe by up to 4,000%, according to allegations made by the Times. The proposal was made in 2014 when the company was in dispute with the Spanish health service. Aspen, which has its European base in Dublin, raised the prices of some of its cancer drugs after purchasing the rights to the Cosmos drug portfolio from GlaxoSmithKline in 2009. Although the Cosmos drugs were out of patent, they had no competition. Aspen was also able to exploit a loophole that enables companies to raise prices once brand names are dropped.